Showing results (1331-1340 of 1,376) with videos related to

Sort By:
Pageof 138
JAMA Neurology|December 30, 2014
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim reportRichard A Nash, George J Hutton, Michael K Racke, et al.
Nature Medicine|August 20, 2025
AI-driven reclassification of multiple sclerosis progressionHabib Ganjgahi, Dieter A Häring, Piet Aarden, et al.
Journal of Burn Care & Research : Official Publication of the American Burn Association|June 23, 2018
Renal Replacement Therapy in Severe Burns: A Multicenter Observational StudyKevin K Chung, Elsa C Coates, William L Hickerson, et al.
Nature Genetics|March 14, 2017
Germline mutations in ABL1 cause an autosomal dominant syndrome characterized by congenital heart defects and skeletal malformationsXia Wang, Wu-Lin Charng, Chun-An Chen, et al.
Prehospital and Disaster Medicine|April 13, 2004
A proposed universal medical and public health definition of terrorismJeffrey L Arnold, Per Ortenwall, Marvin L Birnbaum, et al.
The New England Journal of Medicine|September 3, 2020
Weight Loss in Underserved Patients - A Cluster-Randomized TrialPeter T Katzmarzyk, Corby K Martin, Robert L Newton, et al.
Molecular Biology of the Cell|October 3, 2019
Mitochondrial lipid droplet formation as a detoxification mechanism to sequester and degrade excessive urothelial membranesYi Liao, Daniel K L Tham, Feng-Xia Liang, et al.
Lancet (London, England)|June 14, 2016
Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trialHarold L Atkins, Marjorie Bowman, David Allan, et al.
JAMA Network Open|November 21, 2024
A Hearing Intervention and Health-Related Quality of Life in Older Adults: A Secondary Analysis of the ACHIEVE Randomized Clinical TrialAlison R Huang, Emmanuel Garcia Morales, Michelle L Arnold, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 31, 2023
Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 studyBarry A Singer, Douglas L Arnold, Jelena Drulovic, et al.
Pageof 138